Related Experiment Videos
Reduction in coronary heart disease: clinical and anatomical considerations
L F Satler1, D L Pearle, C E Rackley
1Department of Medicine, Georgetown University Hospital, Washington, DC.
Insights
Lowering cholesterol significantly reduces coronary events and may slow atherosclerosis progression. New statin drugs offer greater lipid reduction and potential plaque regression, improving cardiovascular outcomes.
Area of Science:
- Cardiovascular Medicine
- Atherosclerosis Research
- Lipid Metabolism
Background:
- Current coronary artery disease interventions relieve symptoms but do not halt atherosclerosis.
- The cholesterol-atherogenesis hypothesis is increasingly supported by epidemiological and clinical data.
- Elevated total and LDL cholesterol correlate with increased coronary artery disease risk.
Purpose of the Study:
- To review the evidence linking cholesterol to atherosclerosis and coronary events.
- To assess the impact of cholesterol-lowering interventions on coronary artery disease progression and outcomes.
- To explore the potential of new pharmacologic agents for managing atherosclerosis.
Main Methods:
- Review of epidemiological studies and major clinical trials (e.g., Coronary Drug Project, LRC-CPPT, Helsinki Heart Study, NHLBI Type II, Cholesterol Lowering Atherosclerosis Study).
- Analysis of data on the effects of diet, lifestyle changes, and pharmacologic interventions on lipid levels and atherosclerotic progression.
- Evaluation of the impact of HmG co-A reductase inhibitors on serum lipids and potential for plaque regression.
Main Results:
- Lowering cholesterol has been shown to reduce fatal and nonfatal coronary events.
- Cholesterol reduction is associated with decreased progression of coronary disease and potential plaque regression.
- Pharmacologic cholesterol-lowering typically achieves only 10-20% reduction with side effects; statins offer greater potential.
- Cardiovascular mortality benefits are observed, but age-adjusted total mortality remains unchanged.
Conclusions:
- Cholesterol management is crucial for reducing coronary events and slowing atherosclerosis.
- Newer lipid-lowering drugs like statins may offer enhanced plaque regression potential.
- Future management requires multidisciplinary collaboration for comprehensive patient care.
Abstract:
Coronary artery bypass surgery, percutaneous transluminal coronary angioplasty and thrombolytic therapy in acute myocardial infarction have relieved symptoms, preserved myocardium, and prolonged life but have not modified the progression of atherosclerosis in the coronary arteries. In the last 10 years, however, progress has been made in establishing the cholesterol-atherogenesis hypothesis. Epidemiologic studies have demonstrated that the higher the total plasma cholesterol and low density lipoprotein cholesterol (LDL-C), the greater the risk that coronary artery disease will develop. Recently, clinical trials including the Coronary Drug Project, the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), and the Helsinki Heart Study provided evidence that lowering cholesterol reduces the frequency of fatal and nonfatal coronary events. In addition, the National Heart, Lung, and Blood Institute (NHLBI) Type II Coronary Intervention Study and the Cholesterol Lowering Atherosclerosis Study demonstrated that lowering of cholesterol was associated with a decreased incidence of progression of coronary disease, as well as with the potential for reduction in the atherosclerotic plaque. Beneficial effects of diet and lifestyle changes also have an important effect on atherosclerosis. The impact of lowering cholesterol has been limited primarily by pharmacologic programs which lower cholesterol only 10-20% and are associated with a high incidence of intolerable side effects. With the recent introduction of the HmG co-A reductase inhibitors and their more profound effect on serum lipids, it may be possible to further promote plaque regression. The future of all these interventions, however, must still be assessed by overall mortality; studies to date have demonstrated beneficial effects on cardiovascular mortality but age-adjusted total mortality has remained unchanged. Future management of patients with acute and chronic coronary artery disease will involve a collaboration of cardiologists, endocrinologists, and epidemiologists to coordinate screening, recognition, and treatment of this disease.